Hospitalizations in a cohort of HIV patients in Australia, 1999-2007

AIDS

Volumn 24, Issue 9, 2010, Pages 1329-1339

  Falster, Kathleen ^a,b   Wand, Handan ^a   Donovan, Basil ^a   Anderson, Jonathan ^a   Nolan, David ^c   Watson, Kerrie ^d   Watson, Jo ^e   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e National Association of People Living with HIV/AIDS   (Australia)

Author keywords

AIDS; Antiretroviral therapy; HIV; Hospitalization; Incidence

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ANTIBODY; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGING; ARTICLE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE DURATION; FEMALE; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; DATA COLLECTION; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED;

EID: 77952944674     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328339e245     Document Type: Article

References (31)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte AdA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, Brooks JT. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008; 22:1345-1354.
5. Floris-Moore M, Lo Y, Klein RS, Budner N, Gourevitch MN, Moskaleva G, Schoenbaum EE. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34:331-337.
6. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active anti-retroviral therapy. J Acquir Immune Defic Syndr 2001; 27:143-152.
7. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40:609-616.
8. Hellinger FJ. The changing pattern of hospital care for persons living with HIV: 2000 through 2004. J Acquir Immune Defic Syndr 2007; 45:239-246.
9. Krentz HB, Dean S, Gill MJ. Longitudinal assessment (1995-2003) of hospitalizations of HIV-infected patients within a geographical population in Canada. HIV Med 2006; 7:457-466.
10. Mocroft A, Barry S, Sabin CA, Lepri AC, Kinloch S, Drinkwater A, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS 1999; 13:1255-1261.
11. Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004; 5:437-447.
12. Paul S, Gilbert HM, Lande L, Vaamonde CM, Jacobs J, Malak S, Sepkowitz KA. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 2002; 18:501-506.
13. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
14. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
15. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
16. Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia 1997-2000. HIV Med 2002; 3: 28-36.
17. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993; 88:9-25.
18. Schall R. Estimation in generalized linear models with random effects. Biometrika 1991; 78:719-727.
19. AIHW. Australian hospital statistics 2007-2008. Canberra, Australia: Australian Institute of Health and Welfare (AIHW). Health services series no. 33. Cat. no. HSE 71; 2009.
20. Fielden SJ, Rusch ML, Levy AR, Yip B, Wood E,Harrigan RP, etal. Predicting hospitalization among HIV-infected antiretroviral naive patients starting HAART: determining clinical markers and exploring social pathways. AIDS Care 2008; 20:297-303.
21. Gardner LI, Klein RS, Szczech LA, Phelps RM, Tashima K, Rompalo AM, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 2003; 34:320-330.
22. The HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30:21-26.
23. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
24. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197.
25. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
26. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, Grulich AE. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 2009; 23:2183-2190.
27. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34:165-173.
28. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-1471.
29. Nakhaee F, McDonald A, Black D, Law M. A feasible method for linkage studies avoiding clerical review: linkage of the national HIV/AIDS surveillance databases with the National Death Index in Australia. Aust N Z J Public Health 2007; 31:308-312.
30. Grulich AE, Wan X, Coates M, Day P, Kaldor JM. Validation of a nonpersonally identifying method of linking cancer and acquired immune deficiency syndrome register data. J Epidemiol Biostat 1996; 1:207-212.
31. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses 2007; 23:769-776.